AC Immune’s (ACIU) “Sell (D-)” Rating Reiterated at Weiss Ratings

Weiss Ratings reaffirmed their sell (d-) rating on shares of AC Immune (NASDAQ:ACIU) in a research report released on Wednesday,Weiss Ratings reports.

A number of other equities research analysts also recently issued reports on the stock. Zacks Research raised shares of AC Immune from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 9th. BTIG Research reaffirmed a “buy” rating and issued a $8.00 price objective on shares of AC Immune in a research report on Monday, September 8th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $10.00.

AC Immune Stock Performance

Shares of ACIU stock opened at $3.55 on Wednesday. AC Immune has a 52-week low of $1.43 and a 52-week high of $3.99. The company has a 50-day simple moving average of $2.50 and a two-hundred day simple moving average of $2.07. The company has a market capitalization of $356.46 million, a price-to-earnings ratio of -6.12 and a beta of 1.56.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.05). AC Immune had a negative return on equity of 49.35% and a negative net margin of 174.94%.The firm had revenue of $1.65 million during the quarter, compared to the consensus estimate of $1.98 million. On average, sell-side analysts forecast that AC Immune will post -0.62 EPS for the current fiscal year.

Institutional Trading of AC Immune

A number of institutional investors have recently modified their holdings of ACIU. BVF Inc. IL lifted its stake in shares of AC Immune by 1.5% during the 1st quarter. BVF Inc. IL now owns 19,822,436 shares of the company’s stock valued at $37,068,000 after buying an additional 300,000 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of AC Immune during the 3rd quarter valued at approximately $549,000. Acadian Asset Management LLC lifted its stake in shares of AC Immune by 87.1% during the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock valued at $679,000 after buying an additional 172,796 shares in the last quarter. Banque Cantonale Vaudoise purchased a new stake in shares of AC Immune during the 1st quarter valued at approximately $50,000. Finally, Sei Investments Co. purchased a new stake in shares of AC Immune during the 2nd quarter valued at approximately $51,000. 51.36% of the stock is currently owned by hedge funds and other institutional investors.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.